Inventor · disambiguated record
Werner Heilmayer
Also filed as: HEILMAYER WERNER
15 granted patents·11 pending applications·29 citations·filing 2000–2024
89Inventor score
Files withNabriva Therapeutics GmbH9MANG ROSEMARIE4NABRIVA THERAPEUTICS FORSCHUNG4NABRIVA THERAPEUTICS AG3RIEDL ROSEMARIE3
Top patents by PatentIndex Score
26 records- 0183US8222447B2Organic compoundsMANG ROSEMARIE·Filed 2009·Granted Jul 17, 2012·9 cites·13 claims
- 0283US8071643B2Pleuromutilin derivatives for the treatment of diseases mediated by microbesMANG ROSEMARIE·Filed 2008·Granted Dec 6, 2011·6 cites·11 claims
- 0380US8153689B2Pleuromutilin derivatives for the treatment of diseases mediated by microbesMANG ROSEMARIE·Filed 2011·Granted Apr 10, 2012·4 cites·5 claims
- 0473US7790767B2Pleuromutilin derivatives containing a hydroxyamino- or acyloxyaminocycloalkyl groupNABRIVA THERAPEUTICS FORSCHUNG·Filed 2006·Granted Sep 7, 2010·3 cites·10 claims
- 0573US2022218713A1Pleuromutilin derivatives for the treatment of diseases mediated by microbesNabriva Therapeutics GmbH·Filed 2022·Application pending·0 cites
- 0671US10913703B2Purification of pleuromutilinNabriva Therapeutics GmbH·Filed 2018·Granted Feb 9, 2021·1 cites·20 claims
- 0771US9120727B2Process for the preparation of pleuromutilinsRIEDL ROSEMARIE·Filed 2011·Granted Sep 1, 2015·2 cites·20 claims
- 0870US2021113571A1Pleuromutilin derivatives for the treatment of diseases mediated by microbesNabriva Therapeutics GmbH·Filed 2020·Application pending·0 cites
- 0968US2020281933A1Pleuromutilin derivatives for the treatment of diseases mediated by microbesNabriva Therapeutics GmbH·Filed 2020·Application pending·0 cites
- 1067US8987498B2Enantiomerically pure aminesRIEDL ROSEMARIE·Filed 2011·Granted Mar 24, 2015·1 cites·19 claims
- 1166US6440957B1Cephalosporines having cyclic aminoguanidine substituents as antibioticsBIOCHEMIE GMBH·Filed 2000·Granted Aug 27, 2002·3 cites·8 claims
- 1265US2025009885A1Injectable pharmaceutical formulations of lefamulinNabriva Therapeutics GmbH·Filed 2024·Application pending·0 cites
- 1364US2020030335A1Pleuromutilin derivatives for the treatment of diseases mediated by microbesNabriva Therapeutics GmbH·Filed 2019·Application pending·0 cites
- 1463US2019175603A1Pleuromutilin derivatives for the treatment of diseases mediated by microbesNabriva Therapeutics GmbH·Filed 2019·Application pending·0 cites
- 1563US2014256731A1Pleuromutilin derivatives for the treatment of diseases mediated by microbesNABRIVA THERAPEUTICS AG·Filed 2014·Application pending·0 cites
- 1661US2018303842A1Pleuromutilin derivatives for the treatment of diseases mediated by microbesNabriva Therapeutics GmbH·Filed 2018·Application pending·0 cites
- 1761US2017266194A1Pleuromutilin derivatives for the treatment of diseases mediated by microbesNABRIVA THERAPEUTICS AG·Filed 2017·Application pending·0 cites
- 1859US2009118366A1Organic compoundsNABRIVA THERAPEUTICS FORSCHUNG·Filed 2007·Application pending·0 cites
- 1958US2013040954A1Pleuromutilin derivatives for the treatment of diseases mediated by microbesMANG ROSEMARIE·Filed 2012·Application pending·0 cites
- 2050US12121582B2Injectable pharmaceutical formulations of lefamulinNabriva Therapeutics GmbH·Filed 2016·Granted Oct 22, 2024·0 cites·17 claims
- 2150US8173685B2Pleuromutilin derivatives and their use as antimicrobialsTHIRRING KLAUS·Filed 2008·Granted May 8, 2012·0 cites·19 claims
- 2249US9061980B2Organic compoundsTHIRRING KLAUS·Filed 2008·Granted Jun 23, 2015·0 cites·20 claims
- 2341US7816389B2Organic compoundsNABRIVA THERAPEUTICS FORSCHUNG·Filed 2007·Granted Oct 19, 2010·0 cites·13 claims
- 2441US7485632B2CephalosporinsNABRIVA THERAPEUTICS FORSCHUNG·Filed 2003·Granted Feb 3, 2009·0 cites·10 claims
- 2534US9278920B2Pleuromutilin derivatives for use in the treatment of diseases mediated by microbesRIEDL ROSEMARIE·Filed 2011·Granted Mar 8, 2016·0 cites·12 claims
- 2626US9701628B212-epi pleuromutilinsNABRIVA THERAPEUTICS AG·Filed 2015·Granted Jul 11, 2017·0 cites·17 claims
Join the waitlist — get patent alerts
Get an alert when Werner Heilmayer files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →